LinkedIn Image

Current State-of-the-Art and Future Strategies in Acute Lymphoblastic Leukemia

Meeting Overview

Join us at this satellite symposium to learn about the current and near future strategies of acute lymphocytic leukemia (ALL). You will learn expert insights on how to establish the diagnosis and risk category of patients with newly diagnosed ALL. Furthermore, a summary of the selection of induction therapy, and consolidation and maintenance therapy versus allogeneic stem cell transplantation will be provided. Finally, new strategies in the treatment of relapsed ALL will be highlighted. Attendees will have the opportunity to interact with the expert faculty throughout the symposium.

This interactive educational activity will provide a foundation for further exploration of new treatment options in newly-diagnosed and relapsed/refractory disease.

Current State-of-the-Art and Future Strategies in Acute Lymphoblastic Leukemia is a prIME Oncology satellite symposium to be held at the 22nd Congress of the European Hematology Association.


19.00 Welcome, introduction, and quiz questions
Dieter Hoelzer, MD, PhD
19.05 Diagnosis and risk assessment of acute lymphocytic leukemia in 2017
David I. Marks, MBBS, PhD, FRACP, FRCPath
19.20 Quiz questions
19.25 Making the most of induction therapy in acute lymphocytic leukemia
Dieter Hoelzer, MD, PhD
19.45 Q & A
19.50 Quiz questions
19.55 Minimal residual disease and risk-adapted post-remission therapy
Robin Foà, MD
20.15 Q & A
20.20 Quiz questions
20.25 New strategies for relapsed/refractory acute lymphocytic leukemia
Max S. Topp, MD
20.45 Q & A
20.50 Repeat quiz questions
20.55 Conclusion and key points
Dieter Hoelzer, MD, PhD
21.00 Adjourn


  • Dieter Hoelzer, MD, PhDOnkologikum Frankfurt am Museumsufer
    Frankfurt, Germany
  • Robin Foà, MDUniversity of Rome
    Rome, Italy
  • David I. Marks, MBBS, PhD, FRACP, FRCPathUniversity Hospitals Bristol NHS Foundation Trust
    Bristol, United Kingdom
  • Max S. Topp, MDUniversity of Würzburg
    Würzburg, Germany

Target Audience

This educational activity is designed for hematologists, medical oncologists, and other healthcare providers involved in the management of patients with ALL.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Distinguish standard-risk versus high-risk patients with ALL based upon disease-specific and patient-specific factors
  • Integrate age-adapted protocols into initial therapy of patients with ALL
  • Identify patients with ALL who may avoid allogeneic stem cell transplant in first remission based upon minimal residual disease status and post-induction risk
  • Describe novel therapies demonstrating activity in relapsed/refractory ALL


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Register Now

Date and Location

Thursday, 22 June 2017
19.00 – 21.00

Room N103
IFEMA – Feria de Madrid
Av. Partenón, 5
Madrid, Spain

Printed Materials

Printed Materials


This activity is provided by prIME Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.


prIME Oncology designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Good CME Practice



This educational activity is supported by a grant from Shire.

Sunshine Act/EFPIA Disclosure Code

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.